Sanofi/Regeneron win a new trial on Praluent patents; BridgeBio bankrolls $30M biotech startup
→ After coming perilously close to seeing their PCSK9 drug Praluent jerked off the market, Sanofi and Regeneron have won a new trial in the case involving a rival drug at Amgen. An appeals court is giving their attorneys a green light to raise issues regarding the validity of the patents.
→ BridgeBio is bankrolling a biotech startup to the tune of $30 million. Partnering with MD Anderson, the startup — dubbed Navire Pharma — will fund work on inhibiting SHP2 in fighting cancer tumors. Shafique Virani, a business development exec at Roche/Genentech, has been named the new CEO. “Navire’s compounds potently bind SHP2 and prevent activation of the protein, blocking its ability to promote tumor growth,” said Virani.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.